Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 6276Carcinoma, Renal Cell 1915Urinary Bladder Neoplasms 1672Kidney Neoplasms 931Breast Neoplasms 794Neoplasms 791Carcinoma, Transitional Cell 597Carcinoma, Non-Small-Cell Lung 525Neoplasm Metastasis 511Melanoma 486Ovarian Neoplasms 470Colorectal Neoplasms 456Lung Neoplasms 436Pancreatic Neoplasms 326Testicular Neoplasms 290Stomach Neoplasms 274Sarcoma 267Uterine Cervical Neoplasms 265Non-Muscle Invasive Bladder Neoplasms 264Head and Neck Neoplasms 242Colonic Neoplasms 217Esophageal Neoplasms 203Squamous Cell Carcinoma of Head and Neck 202Carcinoma, Hepatocellular 200Wilms Tumor 196Endometrial Neoplasms 191Recurrence 162Urologic Neoplasms 149Neuroblastoma 148Small Cell Lung Carcinoma 146

Interventions

Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Macular dystrophy, corneal type 1 × Genitourinary × Clear all
NCT04009668 2024-10-30

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

University of Michigan

Phase 2 Completed
7 enrolled 12 charts
Genitourinary

Macular dystrophy, corneal type 1, Glomerulosclerosis, Focal Segmental, Kidney Diseases, Nephrosis, Lipoid, Nephrotic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡